vs
Amneal Pharmaceuticals, Inc.（AMRX）与FMC CORP（FMC）财务数据对比。点击上方公司名可切换其他公司
FMC CORP的季度营收约是Amneal Pharmaceuticals, Inc.的1.3倍（$1.1B vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs -158.8%，领先163.2%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs -11.5%），FMC CORP自由现金流更多（$631.1M vs $108.5M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs 8.6%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
FMC公司是总部位于美国宾夕法尼亚州费城的化工制造企业，1883年创立之初以生产杀虫剂为主，后续逐步拓展业务至其他领域。二战期间曾为美国陆军部设计生产两栖履带登陆车，目前在全球拥有7000名员工，业务布局广泛。
AMRX vs FMC — 直观对比
营收规模更大
FMC
是对方的1.3倍
$814.3M
营收增速更快
AMRX
高出23.0%
-11.5%
净利率更高
AMRX
高出163.2%
-158.8%
自由现金流更多
FMC
多$522.6M
$108.5M
两年增速更快
AMRX
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.1B |
| 净利润 | $35.1M | $-1.7B |
| 毛利率 | 36.5% | 39.8% |
| 营业利润率 | 13.8% | -130.8% |
| 净利率 | 4.3% | -158.8% |
| 营收同比 | 11.5% | -11.5% |
| 净利润同比 | 212.9% | -10457.1% |
| 每股收益（稀释后） | $0.10 | $-13.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXFMC
| Q4 25 | $814.3M | $1.1B | ||
| Q3 25 | $784.5M | $542.2M | ||
| Q2 25 | $724.5M | $1.1B | ||
| Q1 25 | $695.4M | $791.4M | ||
| Q4 24 | $730.5M | $1.2B | ||
| Q3 24 | $702.5M | $1.1B | ||
| Q2 24 | $701.8M | $1.0B | ||
| Q1 24 | $659.2M | $918.0M |
净利润AMRXFMC
| Q4 25 | $35.1M | $-1.7B | ||
| Q3 25 | $2.4M | $-569.3M | ||
| Q2 25 | $22.4M | $66.7M | ||
| Q1 25 | $12.2M | $-15.5M | ||
| Q4 24 | $-31.1M | $-16.3M | ||
| Q3 24 | $-156.0K | $65.0M | ||
| Q2 24 | $6.0M | $295.1M | ||
| Q1 24 | $-91.6M | $-2.7M |
毛利率AMRXFMC
| Q4 25 | 36.5% | 39.8% | ||
| Q3 25 | 34.9% | 23.8% | ||
| Q2 25 | 39.5% | 38.7% | ||
| Q1 25 | 36.8% | 40.0% | ||
| Q4 24 | 36.0% | 42.9% | ||
| Q3 24 | 38.4% | 36.3% | ||
| Q2 24 | 35.6% | 38.3% | ||
| Q1 24 | 36.1% | 37.0% |
营业利润率AMRXFMC
| Q4 25 | 13.8% | -130.8% | ||
| Q3 25 | 9.0% | -73.1% | ||
| Q2 25 | 15.4% | 12.0% | ||
| Q1 25 | 14.4% | 7.4% | ||
| Q4 24 | 10.4% | 19.2% | ||
| Q3 24 | 12.6% | 12.7% | ||
| Q2 24 | 13.6% | 6.0% | ||
| Q1 24 | -1.6% | 8.1% |
净利率AMRXFMC
| Q4 25 | 4.3% | -158.8% | ||
| Q3 25 | 0.3% | -105.0% | ||
| Q2 25 | 3.1% | 6.3% | ||
| Q1 25 | 1.8% | -2.0% | ||
| Q4 24 | -4.3% | -1.3% | ||
| Q3 24 | -0.0% | 6.1% | ||
| Q2 24 | 0.9% | 28.4% | ||
| Q1 24 | -13.9% | -0.3% |
每股收益（稀释后）AMRXFMC
| Q4 25 | $0.10 | $-13.77 | ||
| Q3 25 | $0.01 | $-4.52 | ||
| Q2 25 | $0.07 | $0.53 | ||
| Q1 25 | $0.04 | $-0.12 | ||
| Q4 24 | $-0.10 | $-0.13 | ||
| Q3 24 | $0.00 | $0.52 | ||
| Q2 24 | $0.02 | $2.35 | ||
| Q1 24 | $-0.30 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $584.5M |
| 总债务越低越好 | $2.6B | $3.4B |
| 股东权益账面价值 | $-70.8M | $2.1B |
| 总资产 | $3.7B | $9.7B |
| 负债/权益比越低杠杆越低 | — | 1.62× |
8季度趋势，按日历期对齐
现金及短期投资AMRXFMC
| Q4 25 | $282.0M | $584.5M | ||
| Q3 25 | $201.2M | $497.7M | ||
| Q2 25 | $71.5M | $438.2M | ||
| Q1 25 | $59.2M | $315.3M | ||
| Q4 24 | $110.6M | $357.3M | ||
| Q3 24 | $74.0M | $416.7M | ||
| Q2 24 | $43.8M | $471.5M | ||
| Q1 24 | $46.5M | $417.8M |
总债务AMRXFMC
| Q4 25 | $2.6B | $3.4B | ||
| Q3 25 | $2.6B | $3.4B | ||
| Q2 25 | $2.2B | $3.4B | ||
| Q1 25 | $2.2B | $3.1B | ||
| Q4 24 | $2.4B | $3.1B | ||
| Q3 24 | $2.4B | $3.1B | ||
| Q2 24 | $2.4B | $3.1B | ||
| Q1 24 | $2.4B | $3.1B |
股东权益AMRXFMC
| Q4 25 | $-70.8M | $2.1B | ||
| Q3 25 | $-109.5M | $3.8B | ||
| Q2 25 | $-112.1M | $4.4B | ||
| Q1 25 | $-131.7M | $4.4B | ||
| Q4 24 | $-109.3M | $4.5B | ||
| Q3 24 | $-93.4M | $4.6B | ||
| Q2 24 | $-57.5M | $4.6B | ||
| Q1 24 | $-63.7M | $4.3B |
总资产AMRXFMC
| Q4 25 | $3.7B | $9.7B | ||
| Q3 25 | $3.6B | $12.1B | ||
| Q2 25 | $3.4B | $12.3B | ||
| Q1 25 | $3.4B | $11.8B | ||
| Q4 24 | $3.5B | $11.7B | ||
| Q3 24 | $3.5B | $12.2B | ||
| Q2 24 | $3.5B | $12.1B | ||
| Q1 24 | $3.5B | $12.0B |
负债/权益比AMRXFMC
| Q4 25 | — | 1.62× | ||
| Q3 25 | — | 0.89× | ||
| Q2 25 | — | 0.76× | ||
| Q1 25 | — | 0.71× | ||
| Q4 24 | — | 0.69× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | — | 0.72× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $657.1M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $631.1M |
| 自由现金流率自由现金流/营收 | 13.3% | 58.3% |
| 资本支出强度资本支出/营收 | 2.7% | 2.4% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $-102.5M |
8季度趋势，按日历期对齐
经营现金流AMRXFMC
| Q4 25 | $130.3M | $657.1M | ||
| Q3 25 | $118.5M | $-184.2M | ||
| Q2 25 | $83.8M | $65.9M | ||
| Q1 25 | $7.4M | $-545.0M | ||
| Q4 24 | $118.1M | $427.9M | ||
| Q3 24 | $141.8M | $159.5M | ||
| Q2 24 | $39.7M | $292.2M | ||
| Q1 24 | $-4.4M | $-142.9M |
自由现金流AMRXFMC
| Q4 25 | $108.5M | $631.1M | ||
| Q3 25 | $106.2M | $-207.9M | ||
| Q2 25 | $61.0M | $50.9M | ||
| Q1 25 | $-5.8M | $-576.6M | ||
| Q4 24 | $102.9M | $406.3M | ||
| Q3 24 | $124.8M | $143.8M | ||
| Q2 24 | $29.0M | $282.3M | ||
| Q1 24 | $-13.6M | $-163.6M |
自由现金流率AMRXFMC
| Q4 25 | 13.3% | 58.3% | ||
| Q3 25 | 13.5% | -38.3% | ||
| Q2 25 | 8.4% | 4.8% | ||
| Q1 25 | -0.8% | -72.9% | ||
| Q4 24 | 14.1% | 33.2% | ||
| Q3 24 | 17.8% | 13.5% | ||
| Q2 24 | 4.1% | 27.2% | ||
| Q1 24 | -2.1% | -17.8% |
资本支出强度AMRXFMC
| Q4 25 | 2.7% | 2.4% | ||
| Q3 25 | 1.6% | 4.4% | ||
| Q2 25 | 3.2% | 1.4% | ||
| Q1 25 | 1.9% | 4.0% | ||
| Q4 24 | 2.1% | 1.8% | ||
| Q3 24 | 2.4% | 1.5% | ||
| Q2 24 | 1.5% | 1.0% | ||
| Q1 24 | 1.4% | 2.3% |
现金转化率AMRXFMC
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | 0.99× | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.45× | ||
| Q2 24 | 6.62× | 0.99× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
FMC
| Insecticides | $440.3M | 41% |
| Herbicides | $378.8M | 35% |
| Fungicides | $140.4M | 13% |
| Plant Health | $65.6M | 6% |
| Other | $45.0M | 4% |
